# AIM ImmunoTech (AIM) — Earnings

AIM · AMEX · Stock

Canonical page: https://www.lighthorse.io/tickers/aim/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$1,941.10 |
| EPS estimate | −$4,219.78 |
| EPS surprise | +54.00% |
| Revenue surprise | −75.00% |
| Revenue | $25,000.00 |
| Revenue estimate | $100,000.00 |
| Reported | Aug 14, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/946644/000149315225011986/form10-q.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/format/6c82e687-3dad-b724-a32f-daa321dc4b40.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 14, 2025 | −$4,219.78 | −$1,941.10 | 54.00% | $100,000.00 | $25,000.00 |
| Q4 2024 | Mar 27, 2025 | −$4,747.25 | −$5,274.73 | -11.11% | $100,000.00 | — |
| Q3 2024 | Nov 14, 2024 | −$3,164.84 | −$3,164.84 | 0.00% | $17,500.00 | — |
| Q2 2024 | Aug 14, 2024 | −$6,505.49 | −$1,582.42 | 75.68% | $17,500.00 | $25,000.00 |
| Q1 2024 | May 15, 2024 | −$5,802.20 | −$6,329.67 | -9.09% | — | $40,000.00 |
| Q4 2023 | Apr 1, 2024 | −$6,329.67 | −$13,714.29 | -116.67% | $36,500.00 | $62,000.00 |
| Q3 2023 | Nov 14, 2023 | −$5,978.02 | −$8,439.56 | -41.18% | $24,000.00 | $46,000.00 |
| Q2 2022 | Aug 15, 2022 | −$3,868.13 | −$5,274.73 | -36.36% | $137,667.00 | $15,000.00 |
| Q4 2021 | Mar 31, 2022 | −$4,923.08 | −$6,329.67 | -28.57% | $36,667.00 | $51,000.00 |
| Q4 2020 | Mar 31, 2021 | −$3,868.13 | −$5,274.73 | -36.36% | $353,667.00 | $42,000.00 |
| Q1 2020 | May 14, 2020 | −$7,032.97 | −$11,604.40 | -65.00% | $42,667.00 | $45,000.00 |

## Frequently Asked Questions

### When did AIM ImmunoTech (AIM) last report earnings?

AIM ImmunoTech last reported on Aug 14, 2025, covering fiscal Q2 2025.

### Did AIM beat earnings estimates?

Yes. AIM ImmunoTech reported EPS of −$1,941.10 for Q2 2025 against a −$4,219.78 estimate — a 54.00% beat.

### How much revenue did AIM report last quarter?

AIM ImmunoTech reported $25,000.00 in revenue for Q2 2025, against a consensus estimate of $100,000.00.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).